The agenda for the 28 May 2014 Transparency Commission meeting is now available.  The Commission will examine the following health care technologies:

• Aflibercept (Eylea) - New indication
• Belatacept (Nulojix) - Re-evaluation of SMR
• Tapentadol hydrochloride (Palexia LP) - New formulation
• Belimumab (Benlysta) - Re-evaluation of ASMR

The Commission will also conduct appeal hearings for the following health care technologies: 

• Omega-3-acid etheyl esters (Omacor)
• Coagulation factor VIII (human) with von Willebrand factor (human) (Voncento)

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-05/odj_ct_28042014_internet.pdf